Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex

Angelisa Frasca, Fabio Fumagalli, Judith ter Horst, Giorgio Racagni, Keith J. Murphy, Marco A. Riva
2008 International Journal of Neuropsychopharmacology  
Repeated antipsychotic treatment may produce adaptive changes ranging from cytoarchitectural rearrangements to synaptic modifications that might contribute to clinical improvement. We performed a prolonged treatment (2 wk) with the first-generation antipsychotic (FGA) haloperidol (1 mg/kg) and the second-generation antipsychotic (SGA) olanzapine (2 mg/kg twice daily) and analysed the expression of the polysialylated form of neural cell adhesion molecule (PSA-NCAM) in rat hippocampus and
more » ... ocampus and prefrontal cortex via immunohistochemistry. We found a regional-and drug-selective increase of PSA-NCAM expression in prefrontal cortex of olanzapine-treated rats with no effects in hippocampus ; conversely, haloperidol did not produce a change in either brain region. Our findings reveal a possible role for PSA-NCAM in the mechanism of action of the SGA olanzapine adding complexity as well as specificity to the molecular changes set in motion by this drug.
doi:10.1017/s1461145708009061 pmid:18593508 fatcat:57lxk3tm3fa5rkrwuiozxxtega